RedHill Biopharma's (RDHL) Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
April 9, 2021 7:00 AM EDTTEL AVIV, Israel and RALEIGH, N.C., April 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has received a unanimous recommendation to continue, following a fourth independent Data Safety Monitoring Board (DSMB) safety review. The DSMB's recommendation is based on an analysis of unblinded safety data from the first 255 patients... More
